News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
She joins Enveda from Gilead Sciences
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Subscribe To Our Newsletter & Stay Updated
